Our Mission
TransCode Therapeutics is dedicated to the discovery, development, and delivery of RNA interference (RNAi) therapeutics by overcoming the modality’s greatest challenge – the safe and precise delivery of engineered oligonucleotides to cancer-causing genes to induce regressions without recurrence in patients living with cancer.
Transforming cancer treatment
TransCode Therapeutics, an emerging leader in the development of RNAi oncology therapeutics, was created to realize our belief that cancer can be defeated. Our belief is based on a new approach to address what has been the most intractable challenge in RNA therapeutics: delivering an oligonucleotide to its target before the body’s immune system can attack and dismantle it. Because the TransCode platform is not tumor-specific, it has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, as well as glioblastomas.
At TransCode, we are driven by an urgent need to change how cancer is treated both as a therapeutic modality and in terms of improving patient outcomes. We believe in the ability of RNAi therapeutics to offer patients complete regression of their disease without recurrence rather than the current norm of giving patients additional months of survival. Our expectations are matched by our science, which is ambitious but data-driven, revolutionary but realistic, and is fueled by a passion to find a new way to combat and defeat cancer.
At TransCode, we are driven by an urgent need to change how cancer is treated both as a therapeutic modality and in terms of improving patient outcomes. We believe in the ability of RNAi therapeutics to offer patients complete regression of their disease without recurrence rather than the current norm of giving patients additional months of survival. Our expectations are matched by our science, which is ambitious but data-driven, revolutionary but realistic, and is fueled by a passion to find a new way to combat and defeat cancer.
‘The Box’ Composed by Salmon Laurent David Cohen & Fradji Marshall - Courtesy of APM Music
Our management and advisory team combines decades of oncology drug discovery and development expertise, life science business acumen and Wall Street knowledge to add both scientific insight and valuable strategic perspective to address our market.
Click on each image below to view their bio:
Michael Dudley
Founder, CEO, Director
Founder, CEO, Director
Zdravka Medarova, PhD
Founder/Drug Discovery
Founder/Drug Discovery
Anna Moore, PhD
Founder
Founder
Tom Fitzgerald, MBA
CFO, Director
CFO, Director
Oliver Steinbach, PhD
VP Clinical/Regulatory
VP Clinical/Regulatory
Judy Carmody, PhD
Operations Consultant
Operations Consultant
Keith Flaherty, MD
George Calin, MD, PhD
John Henneman III, JD
Dmitry Samarsky, PhD
Raghu Kalluri, MD, PhD
Philippe Calais, PhD
Alan Freidman
G. Susan Srivatsa, PhD
Betsabeh Madani, MBA
Jerome Lewis, PhD, MBA
Mehmet Yigit, PhD
Option A
- Series A Round (Phase I - Clinical Proof of Concept) - $15M - $40M Series A Convertible Preferred
Option B
- Seed Round (Proof of Delivery in humans – eIND study) $3.7M (Convertible Notes - $1.2M already raised)
- Series A Round (Phase I - Clinical Proof of Concept) - $15M - $40M Series A Convertible Preferred
* Funding can be staged or direct to Phase I (without eIND)
General Inquiries:
Email: info@transcodetherapeutics.com
Address: 6 Liberty Street, #2382, Boston, MA 02109
Phone: 857-301-6857
Address: 6 Liberty Street, #2382, Boston, MA 02109
Phone: 857-301-6857
